# Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy

Study · id `cardio:ct-nct05836753` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05836753](<https://clinicaltrials.gov/study/NCT05836753>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05836753

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05836753. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-07 (actual); primary completion 2023-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05836753, source copy `cardio:ctgov-nct05836753-2023-07-20`, retrieved 2026-10-26)
- Started: 2023-05-07 (actual) (ClinicalTrials.gov record NCT05836753, source copy `cardio:ctgov-nct05836753-2023-07-20`, retrieved 2026-10-26)
- Primary completion: 2023-11 (anticipated) (ClinicalTrials.gov record NCT05836753, source copy `cardio:ctgov-nct05836753-2023-07-20`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05836753, source copy `cardio:ctgov-nct05836753-2023-07-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05836753, source copy `cardio:ctgov-nct05836753-2023-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05836753-2023-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
- Acronym: ESPRIT
- Condition: Ischemic Stroke, Acute
- Intervention (Drug): Sarecycline Tablet
- Intervention (Drug): Placebo tablets of Sarecycline tablets
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Neurodawn Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: Neurodawn Pharmaceutical Co., Ltd. (`cardio:org-neurodawn-pharmaceutical-co-ltd`)

## Provenance

Content hash: 863c60a1f37dd2314291191c8a361745b0be6a16c946ebaba6cc2978b139f6b0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
